Table 3 Key data of 3 study participants infected on enrolment and 2 participants who acquired Plasmodium infections during the study period
Participant | #107 | #124 | #006 |
|---|---|---|---|
Baseline | |||
Date 1 | 21/7/16 | 24/8/16 | 20/5/16 |
Species | Pf | Pv | Not infected |
K13 | C580Y | Not tested | |
ExoE415G | E415G | ||
P14 CNV | Single copy | ||
Pfmdr1 CNV | Single copy | ||
Parasites/ml | 22,225 | 1505 | |
Treatment 1 | ACT + 14 days primaquine (15 mg/day) | ||
Pre-forest entry | |||
Date 2 | 7/8/16 | 9/10/16 | 6/6/16 |
Species | Pf | Not infected | Pf |
K13 | C580Y | Wild type | |
ExoE415G | E415G | Insufficient DNA sample for testing | |
P14 CNV | Multicopies | ||
Pfmdr1 CNV | Single copy | Single copy | |
Parasites/ml | 6412 | 663 | |
Treatment 2 | ACT | ACT | Placebo |
Forest days | 10 | 5 | 20 |
Camp | Not known | Campsitea | Camp 8 Tram 7 |
15 days after return from forest | |||
Date 3 | 6/9/16 | 4/11/16 | 12/7/16 |
Species | Not infected | Pf | Pf |
K13 | C580Y | C580Y | |
ExoE415G | E415G | E415G | |
P14 CNV | Multicopies | Multicopies | |
Pfmdr1 CNV | Single copy | Single copy | |
Parasites/ml | 5142 | 111,500 | |